Device Trends To Watch In 2013

The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, are providing the industry with some momentum going into 2013.

Each year at this time, we look back at the previous year to identify the highs, the lows, and the trends that will shape the future of the medical device industry. In 2012, the theme was headwinds. It was the buzzword CEOs often used at investor presentations to describe the difficult environment the industry is facing – the pending medical device tax, the fiscal cliff negotiations that threatened to cut Medicare physician payments by 26.5% (forestalled, at the moment), pricing pressures, and austerity measures in Europe that have reduced surgical and interventional procedure volumes. In addition, the US Food and Drug Administration (FDA) remains unpredictable, and the decline in device venture investing continues, making financing hard to find for many medical device start-ups. Even markets that have traditionally been the drivers of device growth, most notably interventional cardiology, have seen declines, while growth in other large markets, including cardiac rhythm management and much of orthopedics – particularly hip and knee implants and spine – remains slow. Overlaying all of this is the broad banner of health care reform with its accompanying focus on cost reduction and comparative effectiveness, meaning companies now need to demonstrate the economic as well as the clinical efficacy of new products. Let’s just say that the wind is not at the backs of medical device companies these days.

Still, as any sailor knows, headwinds are an unavoidable reality, the kind of shift in conditions that requires sharp piloting skills and a tight rein on the sails as there...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

 
• By 

BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.

Industry Execs Talk Tariff Turbulence During MD&M East

 

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Business

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

 
• By 

BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By 

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.